Our Pipeline

We have a broad pipeline of programs focused on solid tumors with a lead targeting mesothelin undergoing IND-enabling studies. We also used a CD19-TRuC™-T cells to demonstrate proof of principle in hematology before using the distinct advantages of our platform in the solid tumor setting. We anticipate entering the clinic in 2018.

Lead Program: TC-210

TC-210 is our lead TRuC™-T cell program targeting mesothelin for the treatment of solid tumors including ovarian, pancreatic, lung cancer, mesothelioma and cholangiocarcinoma. Mesothelin is a glycosylphosphatidylinositol (GPI) anchored surface protein that has differential high expression in a range of solid tumors, making it an attractive therapeutic target for TRuC™ intervention. Mesothelin overexpression has also been correlated with poorer prognosis in certain cancer types and plays a role in tumorigenesis.

TC-210 TRuC™-T cells contain engineered T cell receptors that integrate to CD3 epsilon subunit fused with a humanized anti-mesothelin single domain antibody. Preclinical data conducted in mouse xenograft models demonstrated superior antitumor activity for TC-210 compared to CAR-T cells targeting the same antigen. Our scientists also showed that TC-210 can eradicate solid tumors and protect mice from a later tumor re-challenge, suggesting its persistence in solid tumors. Based on the superiority data in vivo, we have initiated IND-enabling studies for TC-210 and expect to enter clinical studies in 2018.

Next Wave: More Solid Tumor TRuC™-T cell Therapies

We are advancing multiple earlier-stage TRuC™-T cell programs towards preclinical development focused on targeting validated solid tumor-associated antigens that are differentially found on tumor cells. We are also exploring novel targets that allow us to address unmet medical needs in an even broader patient population.